Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics

Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics

To date, the current COVID-19 pandemic caused by SARS-CoV-2 has infected 99.2 million while killed 2.2 million people throughout the world and is still spreading widely. The unavailability of potential therapeutics against this virus urges to search and develop new drugs. SARS-CoV-2 enters human cel...

Full description

Bibliographic Details
Main Authors: Abdul Basit, Asad Mustafa Karim, Muhammad Asif, Tanveer Ali, Jung Hun Lee, Jeong Ho Jeon, Shafiq ur Rehman, Sang Hee Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
SARS-CoV-2
RBD
designed peptide
s glycoprotein
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.731828/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.731828/full

Similar Items